3 reasons this ASX 200 stock is one of WAM's 'strategic holdings'

This fund manager has outlined the positive case.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The S&P/ASX 200 Index (ASX: XJO) stock Iress Ltd (ASX: IRE) is a leading idea in the WAM Leaders Ltd (ASX: WLE) portfolio.

Iress is an ASX fintech share that provides software and services for trading and market data, financial advice, investment management, mortgages, superannuation, life and pensions, and data intelligence to the global financial services industry.

Let's take a closer look.

Focused man entrepreneur with glasses working, looking at laptop screen thinking about something intently while sitting in the office.

Image source: Getty Images

What attracted the fund manager to Iress shares?

Iress is currently going through a turnaround through "cost efficiencies and divestment of non-core businesses, which will help reduce its leverage and drive future earnings growth."

The company recently advised its cost base was "more favourable" in the second half, with further efficiencies found.

It conducted a headcount reduction program between May to September. The full effect of the cost reduction program will be felt in FY24.

The company said it continued to evaluate further cost optimisation opportunities at the business unit level. Third-party vendor optimisation will also be a focus for FY24 for the ASX 200 stock.

WAM said Iress was one of its strategic holdings because the catalysts could lead to a "material re-rating of the valuation in the near term".

The fund manager pointed out Iress' trading update during the month, which highlighted the benefits of recent cost reductions and stabilisation in revenue, leading to the company raising its earnings guidance "meaningfully".

The investment team at WAM is still positive about the company as it continues to execute its strategy.

What's the new guidance?

Iress said underlying earnings before interest, tax, depreciation and amortisation (EBITDA) was "trending more favourably" in the second half of FY23.

Its previous guidance for the second half was between $58 million and $62 million, which was upgraded to a range of between $63 million and $68 million.

This meant the guidance range for full-year underlying EBITDA increased from a range of $118 million and $122 million to between $123 million and $128 million.

What about the long-term outlook for the ASX 200 stock?

By the end of FY24, the company is expecting the transformation program to be completed, supported by 'specialist execution consultants'.

There's also going to be a "significant focus on modernising pricing initiatives" and "selective investment into core businesses."

FY24 underlying EBITDA growth of between 5% to 10% is expected, to reach between $135 million to $145 million. By the end of FY24, it's expecting its annualised underlying EBITDA to be between $150 million to $170 million.

By FY25, the business aims to progress to the rule of 40. That's where the revenue growth and profit margin together amount to at least 40. It wants to have a streamlined cost base, as well as significant debt reduction and balance sheet strength.

Iress share price snapshot

Since the start of 2023, the Iress share price is down 16%.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on ASX Share Market News

Six smiling health workers pose for a selfie.
ASX Share Market News

ASX 200 healthcare shares lead a weaker market amid 82% chance of a rate hike

Healthcare shares gained 3.76% while the ASX 200 fell 0.11% last week.

Read more »

A man in his office leans back in his chair with his hands behind his head looking out his window at the city.
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

Wooden house models on a table with a man using a calculator.
Broker Notes

Why this expert believes it's time to exit positions in REA Group shares

One broker is calling time on this ASX 200 stock.

Read more »

A group of young ASX investors sitting around a laptop with an older lady standing behind them explaining how investing works.
ASX Share Market News

Light & Wonder vs Aristocrat Leisure: Which gaming share wins?

Light & Wonder or Aristocrat Leisure: see how the ASX gaming leaders stack up head-to-head – and which one I’d…

Read more »

Five young people sit in a row having fun and interacting with their mobile phones.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a slightly sour end to the trading week this Friday.

Read more »

Two miners at a mine site on their tablets, with mining machinery behind them.
Share Fallers

Why has the Mineral Resources share price fallen 12% this week?

It’s been another tough week for Mineral Resources shareholders.

Read more »

Graphic depicting Australian economic activity.
ASX Share Market News

ASX 200 slips into the red after a positive start. Here's why

The benchmark index is seesawing again.

Read more »

Happy young couple riding a motorbike together.
Broker Notes

7 ASX 200 shares with reaffirmed buy ratings this week

Brokers retained a positive view on Santos, Zip, AMP, and other shares this week. 

Read more »